What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor Treatment of hereditary angioedema, 10/11/2022 Withdrawn

Orphan designation: Adeno-associated virus serotype 5 v...

Feb 20, 2025  0

Human medicines European public assessment report (EPAR): Somavert, pegvisomant, Date of authorisation: 12/11/2002, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): Opfolda, miglustat, Date of authorisation: 26/06/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0